Skip to content

Ketamine treatment for depression: qualitative study exploring patient views

Sagar Jilka, Clarissa Mary Odoi, Emma Wilson, Sazan Meran, Sara Simblett, Til Wykes

BJPsych Open 2021 DOI: 10.1192/bjo.2020.165 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Qualitative study Peer reviewed
Sample size 14
Population Patients with prior diagnoses of depression but no experience of ketamine treatment
Topics Depression Esketamine Ketamine
Key findings Participants were enthusiastic about ketamine treatment for depression but wanted more information, including evidence on long-term safety, before national roll-out. They saw monitoring as necessary to support safe use while raising concerns about misuse of the resulting information, and they wanted patients involved in any future roll-out.

Abstract

Background: Ketamine is a new and promising treatment for depression but comes with challenges to implement because of its potential for abuse.

Aims: We sought the views of patients to inform policy and practical decisions about the clinical use of ketamine before large-scale roll-out is considered.

Method: This qualitative study used three focus groups and three validation sessions from 14 patients with prior diagnoses of depression but no experience of ketamine treatment. Focus groups explored their views about clinical use of ketamine and the best way for ketamine to be administered and monitored. The qualitative data were analysed by three service-user researchers using thematic analysis.

Results: Five themes were generated: changing public perceptions, risks, monitoring, privacy and data protection, and practical aspects. Participants were conscious of the stigma attached to ketamine as a street drug and wanted better public education, and evidence on the safety of ketamine after long-term use. They felt that monitoring was required to provide evidence for ketamine's safe use and administration, but there were concerns about the misuse of this information. Practical aspects included discussions about treatment duration, administration and accessibility (for example who would receive it, under what criteria and how).

Conclusions: Patients are enthusiastic about ketamine treatment but need more information before national roll-out. The wider societal impact of ketamine treatment also needs to be considered and patients need to be part of any future roll-out to ensure its success.

Comparable studies

Other qualitative studies on ketamine for depression, most cited first.

Study Year Design Participants
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. Patients with treatment-resistant depression participating in off-label oral esketamine... 2022 Qualitative study n = 17
A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression Healthcare providers 2022 Quality improvement evaluation with mixed methods n = 94
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Patients with treatment-resistant depression undergoing oral esketamine treatment 2023 Qualitative study using Interpretative Phenomenological Analysis n = 17
A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ project Patients diagnosed with treatment resistant depression (TRD) with experience of... 2021 Qualitative study n = 13
Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences Fee-paying patients with treatment-resistant depression (ages 21–70, 6 females, 6... 2021 Qualitative study n = 12

Explore topics

By condition and practice